Company intelligence / Profile preview

Carinopharm GmbH

Eime / Elze*, Lower Saxony, Germanyzoominfo.com ↗

Ownership: Private
Employees: ~3
Development stage: Commercial

Overview

Carinopharm develops and markets parenteral drugs for cardiology, intensive care, and emergency settings. The company has at least one granted patent for improved intravenous formulations of levosimendan. Its portfolio includes both original products and generics designed for clinical use in hospitals.

Therapeutic areas: OtherCardiovascular
Modalities: Parenteral preparations (including both original and generic drugs); focus on small molecules for intravenous administration
Industry: Biotech

Drug pipeline

2 assets

enoximone

Commercial

Indications: Cardiology

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Carinopharm GmbH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Carinopharm GmbH.

Explore the full profile